Sodium-glucose cotransporter 2 inhibitors and the risk of diabetic ketoacidosis: from pathophysiology to clinical practice
Background: SGLT-2 inhibitors are a novel class of antidiabetic drugs, recently - approved for the treatment of patients with T2DM. Their cardioprotective an...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[2018]
|
| In: |
Cardiovascular & hematological disorders, drug targets
Year: 2018, Jahrgang: 18, Pages: 139-146 |
| ISSN: | 2212-4063 |
| DOI: | 10.2174/1871529X18666180206123149 |
| Online-Zugang: | Resolving-System, Volltext: https://doi.org/10.2174/1871529X18666180206123149 Verlag, Volltext: http://www.eurekaselect.com/159592/article 
|
| Verfasserangaben: | Dimitrios Patoulias, Alexandros Manafis, Christos Mitas, Konstantinos Avranas, Georgios Lales, Ioanna Zografou, Christos Sambanis and Asterios Karagiannis |
| Zusammenfassung: | Background: SGLT-2 inhibitors are a novel class of antidiabetic drugs, recently - approved for the treatment of patients with T2DM. Their cardioprotective an... |
|---|---|
| Beschreibung: | Gesehen am 18.02.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 2212-4063 |
| DOI: | 10.2174/1871529X18666180206123149 |